Guardant Health (GH) reported Thursday Q2 adjusted loss of $0.42 per diluted share, compared with a loss of $0.44 a year earlier.
Analysts polled by FactSet expected loss of $0.39.
Revenue for the quarter ended June 30 was $335.0 million, up from $232.1 million a year ago.
Analysts expected $314.2 million.
The company now expects full year 2026 revenue between $1.34 billion and $1.36 billion, up from $1.30 billion to $1.32 billion earlier. Analysts expect $1.31 billion.